Biomarkers in Tissue Samples From Patients With Ewing Sarcoma
NCT ID: NCT01480518
Last Updated: 2015-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
166 participants
OBSERVATIONAL
2011-12-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with Ewing sarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma
NCT01342783
Biomarker in Tissue Samples From Patients With Ewing Sarcoma
NCT01365949
Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma
NCT01876303
Biomarkers in Patients With Rhabdomyosarcoma
NCT01466283
Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
NCT01062438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To describe the spectrum of GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing sarcoma tumor specimens.
* To determine if there are differences in GGAA-microsatellite polymorphisms in genomic DNA prepared from Ewing sarcoma tumor specimens as compared to non-afflicted European and African normal genomic DNA.
* To determine if GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing's sarcoma tumor specimens correlates with disease outcome in patients treated on COG protocol AEWS0031.
* To determine whether whole-genome amplification introduces alterations in GGAA-microsatellites as compared to non-amplified genomic DNA.
OUTLINE: Genomic PCR is used to amplify the microsatellites in the NR0B1 and GSTM4 promoters. In addition to determining microsatellite size, each microsatellite is sequenced following cloning into the pCR4 vector (Invitrogen) using standard topoisomerase cloning protocols.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
comparative genomic hybridization
gene expression analysis
mutation analysis
polymerase chain reaction
polymorphic microsatellite marker analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Specimens from patients with Ewing sarcoma used for protocol COG-AEWS08B1
* Obtained from patient samples taken from patients enrolled on COG-AEWS0031
* Whole genome-amplified DNA will be used
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Lessnick, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AEWS11B2
Identifier Type: OTHER
Identifier Source: secondary_id
AEWS11B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00083
Identifier Type: REGISTRY
Identifier Source: secondary_id
AEWS11B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.